Effect of dye and conjugation chemistry on the biodistribution profile of near-infrared-labeled nanobodies as tracers for image-guided surgery

Molecular Pharmaceutics

Volumn 14, Issue 4, 2017, Pages 1145-1153

  Debie, Pieterjan ^a   Van Quathem, Jannah ^a   Hansen, Inge ^a   Bala, Gezim ^a   Massa, Sam ^a   Devoogdt, Nick ^a   Xavier, Catarina ^a   Hernot, Sophie ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Biodistribution; In vivo imaging; Nanobodies; Near infrared fluorescence

Indexed keywords

2RS15DNOTAG; CYANINE DYE; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCENT DYE; IRDYE680RD; IRDYE800CW; LYSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2RS15D; NANOBODY; TUMOR MARKER; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; INDOLE DERIVATIVE; IRDYE 800CW; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; BREAST CANCER; CANCER CELL LINE; CARBOXY TERMINAL SEQUENCE; CHEMISTRY; COMPUTER ASSISTED SURGERY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; MOLECULAR IMAGING; MOUSE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; PURIFICATION; RENAL CLEARANCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL LINE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; METABOLISM; NEOPLASMS; NUDE MOUSE; PROCEDURES; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BENZENESULFONATES; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; FEMALE; INDOLES; MICE; MICE, NUDE; MOLECULAR IMAGING; NANOPARTICLES; NEOPLASMS; RECEPTOR, ERBB-2; SINGLE-DOMAIN ANTIBODIES; SPECTROSCOPY, NEAR-INFRARED; SURGERY, COMPUTER-ASSISTED; TISSUE DISTRIBUTION;

EID: 85019039852     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.6b01053     Document Type: Article

References (35)

1. Vahrmeijer, A. L.; Hutteman, M.; van der Vorst, J. R.; van de Velde, C. J. H.; Frangioni, J. V. Image-Guided Cancer Surgery Using near-Infrared Fluorescence. Nat. Rev. Clin. Oncol. 2013, 10 (9), 507-518.
2. van Dam, G. M.; Themelis, G.; Crane, L. M. A.; Harlaar, N. J.; Pleijhuis, R. G.; Kelder, W.; Sarantopoulos, A.; de Jong, J. S.; Arts, H. J. G.; van der Zee, A. G. J.; Bart, J.; Low, P. S.; Ntziachristos, V. Intraoperative Tumor-Specific Fluorescence Imaging in Ovarian Cancer by Folate Receptor-α Targeting: First in-Human Results. Nat. Med. 2011, 17 (10), 1315-1319.
3. Hoogstins, C. E. S.; Tummers, Q. R. J. G.; Gaarenstroom, K. N.; de Kroon, C. D.; Trimbos, J. B. M. Z.; Bosse, T.; Smit, V. T. H. B. M.; Vuyk, J.; van de Velde, C. J. H.; Cohen, A. F.; Low, P. S.; Burggraaf, J.; Vahrmeijer, A. L. A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer. Clin. Cancer Res. 2016, 22 (12), 2929-2938.
4. LI-COR. https://www.licor.com/clinical-translation/registered-clinical-trials.html (accessed 21st June 2016).
5. Bannas, P.; Lenz, A.; Kunick, V.; Well, L.; Fumey, W.; Rissiek, B.; Haag, F.; Schmid, J.; Schütze, K.; Eichhoff, A.; Trepel, M.; Adam, G.; Ittrich, H.; Koch-nolte, F. Molecular Imaging of Tumors with Nanobodies and Antibodies: Timing and Dosage Are Crucial Factors for Improved in Vivo Detection. Contrast Media Mol. Imaging 2015, 10 (5), 367-378.
6. Steeland, S.; Vandenbroucke, R. E.; Libert, C. Nanobodies as Therapeutics: Big Opportunities for Small Antibodies. Drug Discovery Today 2016, 21 (7), 1076-1113.
7. Chakravarty, R.; Goel, S.; Cai, W. Nanobody: The "Magic Bullet" for Molecular Imaging? Theranostics 2014, 4 (4), 386-398.
8. Xavier, C.; Vaneycken, I.; D'huyvetter, M.; Heemskerk, J.; Keyaerts, M.; Vincke, C.; Devoogdt, N.; Muyldermans, S.; Lahoutte, T.; Caveliers, V. Synthesis, Preclinical Validation, Dosimetry, and Toxicity of 68Ga-NOTA-Anti-HER2 Nanobodies for iPET Imaging of HER2 Receptor Expression in Cancer. J. Nucl. Med. 2013, 54 (5), 776-784.
9. Massa, S.; Vikani, N.; Betti, C.; Ballet, S.; Vanderhaegen, S.; Steyaert, J.; Descamps, B.; Vanhove, C.; Bunschoten, A.; van Leeuwen, F. W. B.; Hernot, S.; Caveliers, V.; Lahoutte, T.; Muyldermans, S.; Xavier, C.; Devoogdt, N. Sortase A-Mediated Site-Specific Labeling of Camelid Single-Domain Antibody-Fragments: A Versatile Strategy for Multiple Molecular Imaging Modalities. Contrast Media Mol. Imaging 2016, 11 (5), 328-339.
10. Keyaerts, M.; Xavier, C.; Heemskerk, J.; Devoogdt, N.; Everaert, H.; Ackaert, C.; Vanhoeij, M.; Duhoux, F. P.; Gevaert, T.; Simon, P.; Schallier, D.; Fontaine, C.; Vaneycken, I.; Vanhove, C.; De Greve, J.; Lamote, J.; Caveliers, V.; Lahoutte, T. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma. J. Nucl. Med. 2016, 57 (1), 27-33.
11. Broisat, A.; Hernot, S.; Toczek, J.; De Vos, J.; Riou, L. M.; Martin, S.; Ahmadi, M.; Thielens, N.; Wernery, U.; Caveliers, V.; Muyldermans, S.; Lahoutte, T.; Fagret, D.; Ghezzi, C.; Devoogdt, N. Nanobodies Targeting Mouse/Human VCAM1 for the Nuclear Imaging of Atherosclerotic Lesions. Circ. Res. 2012, 110 (7), 927-937.
12. Blykers, A.; Schoonooghe, S.; Xavier, C.; D'hoe, K.; Laoui, D.; D'Huyvetter, M.; Vaneycken, I.; Cleeren, F.; Bormans, G.; Heemskerk, J.; Raes, G.; De Baetselier, P.; Lahoutte, T.; Devoogdt, N.; Van Ginderachter, J. A.; Caveliers, V. PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments. J. Nucl. Med. 2015, 56 (8), 1265-1271.
13. Vaneycken, I.; Devoogdt, N.; Van Gassen, N.; Vincke, C.; Xavier, C.; Wernery, U.; Muyldermans, S.; Lahoutte, T.; Caveliers, V. Preclinical Screening of Anti-HER2 Nanobodies for Molecular Imaging of Breast Cancer. FASEB J. 2011, 25 (7), 2433-2446.
14. Oliveira, S.; Van Dongen, G. a M. S.; Stigter-Van Walsum, M.; Roovers, R. C.; Stam, J. C.; Mali, W.; Van Diest, P. J.; Van Bergen, En; Henegouwen, P. M. P. Rapid Visualization of Human Tumor Xenografts through Optical Imaging with a near-Infrared Fluorescent Anti-Epidermal Growth Factor Receptor Nanobody. Mol. Imaging 2012, 11 (1), 33-46.
15. Kijanka, M.; Warnders, F.-J.; El Khattabi, M.; Lub-de Hooge, M.; van Dam, G. M.; Ntziachristos, V.; de Vries, L.; Oliveira, S.; van Bergen en Henegouwen, P. M. P. Rapid Optical Imaging of Human Breast Tumour Xenografts Using Anti-HER2 VHHs Site-Directly Conjugated to IRDye 800CW for Image-Guided Surgery. Eur. J. Nucl. Med. Mol. Imaging 2013, 40 (11), 1718-1729.
16. Kijanka, M. M.; van Brussel, A. S. A.; van der Wall, E.; Mali, W. P. T. M.; van Diest, P. J.; van Bergen en Henegouwen, P. M. P.; Oliveira, S. Optical Imaging of Pre-Invasive Breast Cancer with a Combination of VHHs Targeting CAIX and HER2 Increases Contrast and Facilitates Tumour Characterization. EJNMMI Res. 2016, 6, 14.
17. van Brussel, A. S. A.; Adams, A.; Oliveira, S.; Dorresteijn, B.; El Khattabi, M.; Vermeulen, J. F.; van der Wall, E.; Mali, W. P. T. M.; Derksen, P. W. B.; van Diest, P. J.; van Bergen en Henegouwen, P. M. P. Hypoxia-Targeting Fluorescent Nanobodies for Optical Molecular Imaging of Pre-Invasive Breast Cancer. Mol. Imaging Biol. 2016, 18 (4), 535-544.
18. Bannas, P.; Well, L.; Lenz, A.; Rissiek, B.; Haag, F.; Schmid, J.; Hochgräfe, K.; Trepel, M.; Adam, G.; Ittrich, H.; Koch-Nolte, F. In Vivo near-Infrared Fluorescence Targeting of T Cells: Comparison of Nanobodies and Conventional Monoclonal Antibodies. Contrast Media Mol. Imaging 2014, 9 (2), 135-142.
19. Massa, S.; Xavier, C.; Muyldermans, S.; Devoogdt, N. Emerging Site-Specific Bioconjugation Strategies for Radioimmunotracer Development. Expert Opin. Drug Delivery 2016, 13 (8), 1149-1163.
20. Massa, S.; Xavier, C.; De Vos, J.; Caveliers, V.; Lahoutte, T.; Muyldermans, S.; Devoogdt, N. Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging. Bioconjugate Chem. 2014, 25 (5), 979-988.
21. Junutula, J. R. J. R.; Raab, H.; Clark, S.; Bhakta, S.; Leipold, D. D. D.; Weir, S.; Chen, Y.; Simpson, M.; Tsai, S. P. S. P.; Dennis, M. S. M. S.; Lu, Y.; Meng, Y. G.; Ng, C.; Yang, J.; Lee, C. C.; Duenas, E.; Gorrell, J.; Katta, V.; Kim, A.; McDorman, K.; Flagella, K.; Venook, R.; Ross, S.; Spencer, S. D.; Lee Wong, W.; Lowman, H. B.; Vandlen, R.; Sliwkowski, M. X.; Scheller, R. H.; Polakis, P.; Mallet, W.; et al. Site-Specific Conjugation of a Cytotoxic Drug to an Antibody Improves the Therapeutic Index. Nat. Biotechnol. 2008, 26 (8), 925-932.
22. Strop, P.; Liu, S. H.; Dorywalska, M.; Delaria, K.; Dushin, R. G.; Tran, T. T.; Ho, W. H.; Farias, S.; Casas, M. G.; Abdiche, Y.; Zhou, D.; Chandrasekaran, R.; Samain, C.; Loo, C.; Rossi, A.; Rickert, M.; Krimm, S.; Wong, T.; Chin, S. M.; Yu, J.; Dilley, J.; Chaparro-Riggers, J.; Filzen, G. F.; O'Donnell, C. J.; Wang, F.; Myers, J. S.; Pons, J.; Shelton, D. L.; Rajpal, A. Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates. Chem. Biol. 2013, 20 (2), 161-167.
23. Oliveira, S.; Cohen, R.; Walsum, M.; van Dongen, G. A.; Elias, S. G.; van Diest, P. J.; Mali, W.; van Bergen en Henegouwen, P. M. P. A Novel Method to Quantify IRDye800CW Fluorescent Antibody Probes Ex Vivo in Tissue Distribution Studies. EJNMMI Res. 2012, 2 (1), 50.
24. Lemaire, M.; D'Huyvetter, M.; Lahoutte, T.; Van Valckenborgh, E.; Menu, E.; De Bruyne, E.; Kronenberger, P.; Wernery, U.; Muyldermans, S.; Devoogdt, N.; Vanderkerken, K. Imaging and Radioimmunotherapy of Multiple Myeloma with Anti-Idiotypic Nanobodies. Leukemia 2014, 28 (2), 444-447.
25. Keyaerts, M.; Verschueren, J.; Bos, T. J.; Tchouate-Gainkam, L. O.; Peleman, C.; Breckpot, K.; Vanhove, C.; Caveliers, V.; Bossuyt, A.; Lahoutte, T. Dynamic Bioluminescence Imaging for Quantitative Tumour Burden Assessment Using IV or IP Administration of D-Luciferin: Effect on Intensity, Time Kinetics and Repeatability of Photon Emission. Eur. J. Nucl. Med. Mol. Imaging 2008, 35 (5), 999-1007.
26. Sato, K.; Nagaya, T.; Nakamura, Y.; Harada, T.; Nani, R. R.; Shaum, J. B.; Gorka, A. P.; Kim, I.; Paik, C. H.; Choyke, P. L.; Schnermann, M. J.; Kobayashi, H. Impact of C4′- O -Alkyl Linker on in Vivo Pharmacokinetics of Near-Infrared Cyanine/Monoclonal Antibody Conjugates. Mol. Pharmaceutics 2015, 12 (9), 3303-3311.
27. Sato, K.; Gorka, A. P.; Nagaya, T.; Michie, M. S.; Nani, R. R.; Nakamura, Y.; Coble, V. L.; Vasalatiy, O. V.; Swenson, R. E.; Choyke, P. L.; Schnermann, M. J.; Kobayashi, H. Role of Fluorophore Charge on the in Vivo Optical Imaging Properties of Near-Infrared Cyanine Dye/Monoclonal Antibody Conjugates. Bioconjugate Chem. 2016, 27 (2), 404-413.
28. Bao, K.; Nasr, K. A.; Hyun, H.; Lee, J. H.; Gravier, J.; Gibbs, S. L.; Choi, H. S. Charge and Hydrophobicity Effects of NIR Fluorophores on Bone-Specific Imaging. Theranostics 2015, 5 (6), 609-617.
29. Bunschoten, A.; Van Willigen, D. M.; Buckle, T.; Van Den Berg, N. S.; Welling, M. M.; Spa, S. J.; Wester, H. J.; Van Leeuwen, F. W. B. Tailoring Fluorescent Dyes to Optimize a Hybrid RGD-Tracer. Bioconjugate Chem. 2016, 27 (5), 1253-1258.
30. Choi, H. S.; Gibbs, S. L.; Lee, J. H.; Kim, S. H.; Liu, F.; Hyun, H.; Park, G.; Xie, Y.; Bae, S.; Frangioni, J. V. Targeted Zwitterionic near-Infrared Fluorophores for Improved Optical Imaging. Nat. Biotechnol. 2013, 31 (2), 148-153.
31. Choi, H. S.; Nasr, K.; Alyabyev, S.; Feith, D.; Lee, J. H.; Kim, S. H.; Ashitate, Y.; Hyun, H.; Patonay, G.; Strekowski, L.; Henary, M.; Frangioni, J. V. Synthesis and in Vivo Fate of Zwitterionic near-Infrared Fluorophores. Angew. Chem., Int. Ed. 2011, 50 (28), 6258-6263.
32. D'Huyvetter, M.; Aerts, A.; Xavier, C.; Vaneycken, I.; Devoogdt, N.; Gijs, M.; Impens, N.; Baatout, S.; Ponsard, B.; Muyldermans, S.; Caveliers, V.; Lahoutte, T. Development of 177Lu-Nanobodies for Radioimmunotherapy of HER2-Positive Breast Cancer: Evaluation of Different Bifunctional Chelators. Contrast Media Mol. Imaging 2012, 7 (2), 254-264.
33. Bannas, P.; Lenz, A.; Kunick, V.; Fumey, W.; Rissiek, B.; Schmid, J.; Haag, F.; Leingärtner, A.; Trepel, M.; Adam, G.; Koch-Nolte, F. Validation of Nanobody and Antibody Based in Vivo Tumor Xenograft NIRF-Imaging Experiments in Mice Using Ex Vivo Flow Cytometry and Microscopy. J. Visualized Exp. 2015, 98, e52462.
34. English, D. P.; Roque, D. M.; Santin, A. D. HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies. Mol. Diagn. Ther. 2013, 17 (2), 85-99.
35. Fabi, a; Di Benedetto, a; Metro, G.; Perracchio, L.; Nistico, C.; Di Filippo, F.; Ercolani, C.; Ferretti, G.; Melucci, E.; Buglioni, S.; Sperduti, I.; Papaldo, P.; Cognetti, F.; Mottolese, M. Her2 Protein and Gene Variation Between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care. Clin. Cancer Res. 2011, 17 (7), 2055-2064.